SCHEMBL7069730

SCHEMBL7069730

N[C@H](/C=C\CCc1c[nH]cn1)CC1CCCCC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7624480 1.00
SCHEMBL7619020 1.00
SCHEMBL7624474 1.00
SCHEMBL7069780 0.79 CDK1 (0.33)
SCHEMBL7069783 0.79 CDK1 (0.33)
SCHEMBL7069782 0.79 CDK1 (0.33)
SCHEMBL7784089 0.78
SCHEMBL7786451 0.78
SCHEMBL8524329 0.72 HRH4 (0.41)
SCHEMBL7786335 0.71

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6166060-A 1H-4(5)-substituted imidazole derivatives GLIATECH, INC. (US) 2000-12-26 US claimed
EP-1320364-A1 THE USE OF HISTAMINE H3-RECEPTOR INVERSE AGONISTS FOR THE CONTROL OF APPETITE AND TREATMENT OF OBESITY GLIATECH, INC. (US) 2003-06-25 EP disclosed
US-20030069295-A1 Use of histamine H3 receptor inverse agonists for the control of appetite and treatment of obesity GLIATECH, INC. 2003-04-10 US disclosed
WO-2002015905-A1 THE USE OF HISTAMINE H3 RECEPTOR INVERSE AGONISTS FOR THE CONTROL OF APPETITE AND TREATMENT OF OBESITY GLIATECH, INC. (US) 2002-02-28 WO disclosed